Drugs / Casopitant
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT00511823 | Jul → Sep 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00440128 | May 2007 → Jul 2008 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00460707 | Apr → Aug 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00437229 | Feb → May 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00405080 | Nov 2006 → Jan 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00404274 | Nov 2006 → Mar 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00404378 | Oct 2006 → Jan 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00358813 | Sep 2006 → Aug 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00332046 | Jan 2006 → ? | social phobia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00359177 | Dec 2005 → Oct 2006 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00334646 | Aug 2005 → Oct 2009 | chemotherapy-induced toxicity | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT00354809 | May 2006 → Jul 2007 | insomnia, sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00280423 | Jan 2006 → Feb 2007 | insomnia, sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00332319 | Jan 2006 → Feb 2007 | overactive bladder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00280436 | Jan 2006 → Mar 2007 | insomnia, sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00358410 | Jan → Aug 2006 | dyspepsia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00321477 | Dec 2005 → Feb 2007 | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00413023 | Jun 2005 → Sep 2006 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00274690 | Feb → Aug 2005 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00169572 | Feb 2005 → ? | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00104403 | Dec 2004 → Jan 2006 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | Mixed |
| Phase 2 | NCT00102492 | Oct 2004 → Sep 2006 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00650871 | Jul 2004 → Aug 2005 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 35 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT00601172 | Mar 2008 → Apr 2009 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00431236 | Nov 2006 → Oct 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00366834 | Jul 2006 → Oct 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00326248 | Mar → Jul 2006 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00334152 | Mar → Jul 2006 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00891761 Comparator | Sep 2009 → Jul 2010 | cancer, chemotherapy-induced toxicity | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2009-09-27 | GlaxoSmithKline | Regulatory GSK provides update on regulatory filings for Zunrisa/Rezonic gsk.com ↗
Consequently, all on-going regulatory files for casopitant are being withdrawn. |
| 2009-06-22 | GlaxoSmithKline | Regulatory Regulatory update for REZONIC™ (casopitant mesylate) gsk.com ↗
GlaxoSmithKline (NYSE: GSK) confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-09-27 | GlaxoSmithKline | GSK provides update on regulatory filings for Zunrisa/Rezonic gsk.com ↗ |
| 2009-06-22 | GlaxoSmithKline | Regulatory update for REZONIC™ (casopitant mesylate) gsk.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | casopitant | “Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant” PMID 19834961 ↗ Dec 2009 |
| Known as | Casopitant mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672054 ↗ |
| Known as | casopitant mesylate | “This randomized, double-blind, dose-ranging, placebo-controlled, phase 2 trial evaluated the neurokinin-1 receptor antagonist casopitant mesylate in combination with...” PMID 19834961 ↗ Dec 20091“Patients were randomly assigned to also receive placebo (n=269), single oral dose of casopitant mesylate (150 mg oral, n=271), or 3-day intravenous plus oral casopitant...” PMID 19428297 ↗ May 2009 |
| Known as | GW-679769B | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672054 ↗ |
| Known as | GW679769 | “Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.” NCT00437229 ↗22“Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]” NCT00404378 ↗ “A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers” NCT00404274 ↗ “The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer” NCT00440128 ↗ “Casopitant (GW679769) oral tablets” NCT00366834 ↗ “GW679769 (Casopitant) oral tablets” NCT00405080 ↗ “Oral Casopitant (GW679769)” NCT00431236 ↗ |
| Known as | Rezonic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672054 ↗ |
| Known as | Zunrisa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1672054 ↗ |
| Action | Inhibit | “Neurokinin 1 receptor antagonist” CHEMBL1672054 ↗1“NK1 antagonist GW679769” NCT00358410 ↗ |
| Modality | Small molecule | — CHEMBL1672054 ↗ |
| Route | Oral | “either oral placebo or casopitant at doses of 50 mg, 100 mg, or 150 mg daily” PMID 19834961 ↗ Dec 2009 |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL1672054 ↗ |